Mississippi is now following Texas and a handful of other states, by positioning itself on the frontier of a potential neurological revolution. On March 19, 2026, Mississippi Governor Tate Reeves made history by signing HB 314 into law, authorizing the Mississippi State Department of Health to use $5 million of Mississippi’s opioid settlement money to fund clinical trials for the drug ibogaine. The bill takes effect July 1 and allows Mississippi to coordinate trials with other states, including Texas, which has already committed to its own program.

A psychoactive substance derived from the root of a plant native to Africa, ibogaine has been used for centuries in spiritual and healing ceremonies. More recently, it has gained scientific interest for its potential to treat opioid and cocaine addiction. Research suggests it increases signaling of important brain molecules linked to drug addiction and depression. Currently a Schedule I controlled substance, Americans seeking treatment must travel abroad at costs that reportedly reach up to $50,000 per session.

As stated by Dr. Nolan Williams, who was involved in the landmark 2024 Stanford University study that brought attention to the use of ibogaine for brain injury, “no other drug has ever been able to alleviate the functional and neuropsychiatric symptoms of traumatic brain injury.”